Nature magazine honors Dr. Feldman with profiling her career highlights and her new role as director of the A. Alfred Taubman Medical Research Institute. She wants to promote high-risk, high-reward research which is typically not funded in today’s competitive climate. Her research includes the pursuit of stem-cell-based ALS therapies. Her colleagues are excited to have a leader eager to take risks at a time when most academics put forth conservative proposals to secure funding from the National Institutes of Health.
Neurologist and research scientist Eva Feldman, M.D., Ph.D., has been selected to direct the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School. The Institute was established in September, through a $22 million gift from the retail pioneer whose name it bears. Read the full article here.
With his $22 million gift to create the A. Alfred Taubman Medical Research Institute and support research at the U-M Medical School, Mr. Taubman has solidified his position as one of the leading donors to the University of Michigan. Only Stephen Ross has given more in his lifetime.
Mr. Taubman’s cumulative giving to the University now stands at more than $60 million – more than $56 million of which has been given as part of the University’s $2.5 billion Michigan Difference campaign. Read the full article here.
ROCKVILLE, Md., Aug. 30 /PRNewswire-FirstCall/ — Stem cell company, Neuralstem, Inc. (Amex: CUR – News), today announced it has entered into a collaborative agreement with the ALS Clinic at University of Michigan Health System, directed by Eva Feldman, M.D., Ph.D., the De Jong Professor of Neurology at the U-M Medical School. The goal of the collaboration is to provide further proof-of-principle data to move Neuralstem’s spinal cord stem cells into patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s disease. ALS is a motor neuron disease, which strikes people between the ages of 40 and 70. As many as 30,000 Americans have the disease at any given time. Read the full article here.
A new $5 million gift by philanthropist and retail pioneer A. Alfred Taubman is making news today, including a major story in the Detroit News and a story on the Michigan Associated Press wire that is being picked up by many news outlets around the state. Mr. Taubman is giving the gift to support research on amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease, led by Eva Feldman, M.D., Ph.D., of Neurology. Part of the research, which will test the use of embryonic stem cells as a potential treatment for this deadly nerve disease, will be performed in collaboration with Martin Marsala, M.D., of the University of California, San Diego School of Medicine. Read the UMHS press release about the gift here.
A week after profiling Eva Feldman, M.D., Ph.D., Neurology, the Detroit News has followed up with a story on the benefit gala held this past weekend to raise money for her laboratory’s research on ALS, also known as Lou Gehrig’s disease.
The front page of the features section in today’s Detroit News contains a major profile of Eva Feldman, M.D., Ph.D., Neurology, including several photos. The article, by columnist Marney Rich Keenan, focuses on Dr. Feldman’s longtime friendship with business leader and U-M donor A. Alfred Taubman, who has been both her patient and a benefactor of her research. The article also mentions a gala event that Mr. Taubman will host this weekend, to raise money for research by Dr. Feldman’s group on amyotrophic lateral sclerosis, ALS, also known as Lou Gehrig’s disease.
A major story in this week’s Crain’s Detroit Business focuses on the research of Eva Feldman, M.D., Ph.D., and the financial support she has received from major donors. The story especially looks at support for her research on ALS (Lou Gehrig’s Disease). It also promotes a fundraising event that was held on Sept.16 to raise money for her team’s work. The event is being hosted by U-M donor Alfred Taubman. The story is available online to subscribers only, or you can request the story from public relations at 734-764-2220.
By coincidence, two newspapers ran major feature stories involving Eva Feldman, M.D., Ph.D., Neurology, on the same day – – giving readers across southeastern Michigan a chance to learn about her research and the clinical trials she is currently leading. In the joint Sunday edition of the Detroit Free Press and Detroit News, Free Press columnist Susan Ager wrote of her experience as a participant in Dr. Feldman’s trial for people with mild nerve damage related to Type 1 diabetes – – and along the way, educated readers about the process of taking part in clinical research. In addition to Dr. Feldman and research nurse Cynthia Plunkett, RNC, the story also quotes Dan Clauw, MD, director of the Center for the Advancement of Clinical Research, and directs readers to the Engage web site to learn more about clinical trials at U-M. The second story, in the Ann Arbor News, focused on Dr. Feldman’s research in diabetes but also in ALS (Lou Gehrig’s disease) and other nerve disorders.
On Sunday, Feb. 19, CNBC at 7 p.m. aired an episode of the diabetes show “dLife” featuring Eva Feldman, M.D., Ph.D., the DeJong Professor of Neurology at the U-M Medical School. Dr. Feldman discussed the latest research in diabetes, including how people with diabetes can take part in clinical trials. She was also featured in a segment on the search for a cure for diabetes. Different cable systems offer CNBC on different channels; check your provider’s listings.
The dLife TV show is a weekly television series for the diabetes community that is focused on information, inspiration, and lifestyle issues in an entertaining format. It can also be seen on satellite television, and segments are available online after their airdate at www.dlife.com.